Orajel Gum Pain 3x Medicated

Benzocaine, Menthol, Zinc Chloride


Church & Dwight Co., Inc.
Human Otc Drug
NDC 10237-792
Orajel Gum Pain 3x Medicated also known as Benzocaine, Menthol, Zinc Chloride is a human otc drug labeled by 'Church & Dwight Co., Inc.'. National Drug Code (NDC) number for Orajel Gum Pain 3x Medicated is 10237-792. This drug is available in dosage form of Gel. The names of the active, medicinal ingredients in Orajel Gum Pain 3x Medicated drug includes Benzocaine - 200 mg/g Menthol, Unspecified Form - 2.6 mg/g Zinc Chloride - 1.5 mg/g . The currest status of Orajel Gum Pain 3x Medicated drug is Active.

Drug Information:

Drug NDC: 10237-792
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Orajel Gum Pain 3x Medicated
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Benzocaine, Menthol, Zinc Chloride
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Church & Dwight Co., Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Gel
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:BENZOCAINE - 200 mg/g
MENTHOL, UNSPECIFIED FORM - 2.6 mg/g
ZINC CHLORIDE - 1.5 mg/g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 17 Dec, 2019
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 22 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part348
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2024
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Church & Dwight Co., Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:2362013
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
NUI:N0000185508
N0000175629
N0000184306
M0000728
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:U3RSY48JW5
L7T10EIP3A
86Q357L16B
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Standardized Chemical Allergen [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class PE:Increased Histamine Release [PE]
Cell-mediated Immunity [PE]
Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`.
Pharmacologic Class CS:Allergens [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Allergens [CS]
Cell-mediated Immunity [PE]
Copper Absorption Inhibitor [EPC]
Decreased Copper Ion Absorption [PE]
Increased Histamine Release [PE]
Standardized Chemical Allergen [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
10237-792-121 TUBE in 1 PACKAGE (10237-792-12) / 3.5 g in 1 TUBE17 Dec, 2019N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose oral pain reliever and oral astringent

Product Elements:

Orajel gum pain 3x medicated benzocaine, menthol, zinc chloride benzocaine benzocaine water polyethylene glycol 400 methyl salicylate saccharin sodium saccharin sorbic acid zinc chloride zinc cation peg-75 lanolin menthol, unspecified form menthol, unspecified form ammonium glycyrrhizate glycyrrhizin

Indications and Usage:

Use for the temporary relief of pain due to minor irritation or injury of the mouth and gums

Warnings:

Warnings methemoglobinemia warning : use of this product may cause methemoglobinemia, a serious condition that must be treated promptly because it reduces the amount of oxygen carried in blood. this can occur even if you have used this product before. stop use and seek immediate medical attention if you or a child in your care develops: pale, gray, or blue colored skin (cyanosis), headache, rapid heart rate, shortness of breath, dizziness or lightheadedness, fatigue or lack of energy allergy alert : do not use this product if you have a history of allergy to local anesthetics such as procaine, butacaine, benzocaine or other "caine" anesthetics

Do Not Use:

Warnings methemoglobinemia warning : use of this product may cause methemoglobinemia, a serious condition that must be treated promptly because it reduces the amount of oxygen carried in blood. this can occur even if you have used this product before. stop use and seek immediate medical attention if you or a child in your care develops: pale, gray, or blue colored skin (cyanosis), headache, rapid heart rate, shortness of breath, dizziness or lightheadedness, fatigue or lack of energy allergy alert : do not use this product if you have a history of allergy to local anesthetics such as procaine, butacaine, benzocaine or other "caine" anesthetics

Dosage and Administration:

Directions adults and children 2 years of age and older apply to affected area up to 4 times daily or as directed by a dentist or doctor children between 2 and 12 years of age ask a doctor before use. should be supervised in the use of this product children under 2 years of age do not use

Stop Use:

Stop use and ask a doctor if symptoms do not improve in 7 days swelling, rash or fever develops irritation, pain or redness persists or worsens

Package Label Principal Display Panel:

Principal display panel #1 oral pain reliever brand for adults open tube tip orajel gum pain 3x medicated gel instant pain relief 20% benzocaine to relieve gum pain cooling relief to soothe gums relieves gum irritation oral pain reliever/astringent net wt 0.125oz (3.5g) cr2_da2044058_ojfc-00500-01_72016656

Further Questions:

Questions or comments? call us at 1-800-952-5080 m-f 9am-5pm et or visit our website at www.orajel.com


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.